Check out your Company Bowl for anonymous work chats.
iRhythm Technologies, Inc. and Quentin Blackford have been recognized by Newsweek and Plant-A Insights Group as one of America’s Greatest Workplaces for Leadership 2026. The distinction highlights organizations that foster trust, accountability and growth through strong leadership, creating workplace cultures where employees feel supported, empowered and confident in their organization's future. Learn more about what makes this company stand out on Newsweek.
America's Greatest Workplaces for Leadership 2026
Every patient’s journey is different and can sometimes lead to unexpected discoveries. Charissa shares her personal experience navigating questions about her heart health and how wearing a Zio cardiac monitor enabled the diagnostic process that followed. Hear her story, in her own words:
Charissa’s unexpected heart journey
Wellness is not a moment, it is part of our culture. Each April, iRhythm celebrates Wellness Month 2026, aligned with our commitment to Better Health for All. Through global experiences, onsite moments, and strong partnerships across teams, we’re strengthening connection, belonging, and wellbeing for the whole person. We’re also observing Wellness Day on April 15, a company‑wide pause to recharge and foster community, as part of our year‑round, culture‑driven investment in our people. This investment reflects how we Strive for Better by seeking diverse perspectives and shared experiences.
Wellness is not a moment, it is part of our culture. Each April, iRhythm celebrates Wellness Month 2026, aligned with our commitment to Better Health for All. Through global experiences, onsite moments, and strong partnerships across teams, we’re strengthening connection, belonging, and wellbeing for the whole person. We’re also observing Wellness Day on April 15, a company‑wide pause to recharge and foster community, as part of our year‑round, culture‑driven investment in our people. This investment reflects how we Strive for Better by seeking diverse perspectives and shared experiences.
iRhythm and Lucem Health have formed a strategic partnership to introduce a predictive AI solution to accelerate early identification of undiagnosed arrhythmias in patient populations with comorbid conditions. Traditional care models often rely on reactive diagnosis, leaving many arrhythmias undetected until stroke, hospitalization, or worse. The aim is to shift that paradigm. And support population health strategies and value-based care goals at scale. Learn more: https://bit.ly/4lUzups The predictive-AI solution does not represent the functionality of any Zio branded medical device.
https://bit.ly/4lUzups
Important Notice: We’ve been made aware of fraudulent individuals posing as iRhythm recruiters. Please note that all legitimate communications from iRhythm will come from verified company email addresses ending in @irhythmtech.com. We will never use generic email services (e.g., Gmail, Yahoo) to contact candidates. If you receive a suspicious message, do not respond and report it to us immediately at taops@irhythmtech.com.
We’ve officially launched in Japan — the second largest ambulatory cardiac monitoring market in the world. Starting this month, our Zio® long-term continuous monitoring (LTCM) service — introduced locally as the Zio® ECG Recording and Analysis System — will begin reaching patients and clinicians in Japan, offering up to 14 days of continuous, uninterrupted, patch-based monitoring. We’re proud to bring our AI-powered heart monitoring service to more people — and to take this important step in expanding our global impact in support of better data, better insights, and better health for all. Our Zio LTCM service will be available in Japan through our exclusive and valued distribution partner, Senko Medical Instrument. Learn more here: https://bit.ly/3GzkRIu hashtag#iRhythm hashtag#Zio hashtag#CardiacMonitoring hashtag#AIinHealthcare hashtag#Japan hashtag#DigitalHealth hashtag#Arrhythmia hashtag#ECGMonitoring Activate to view larger image,
We’ve officially launched in Japan — the second largest ambulatory cardiac monitoring market in the world. Starting this month, our Zio® long-term continuous monitoring (LTCM) service — introduced locally as the Zio® ECG Recording and Analysis System — will begin reaching patients and clinicians in Japan, offering up to 14 days of continuous, uninterrupted, patch-based monitoring. We’re proud to bring our AI-powered heart monitoring service to more people — and to take this important step in expanding our global impact in support of better data, better insights, and better health for all. Our Zio LTCM service will be available in Japan through our exclusive and valued distribution partner, Senko Medical Instrument. Learn more here: https://bit.ly/3GzkRIu hashtag#iRhythm hashtag#Zio hashtag#CardiacMonitoring hashtag#AIinHealthcare hashtag#Japan hashtag#DigitalHealth hashtag#Arrhythmia hashtag#ECGMonitoring Activate to view larger image,
We announced the commercial launch of our Zio monitor and Zio long-term continuous monitoring service in Austria, the Netherlands, Spain, and Switzerland. This is an important milestone as the global burden of arrhythmias continues to rise. Learn more here: https://bit.ly/4giljsb
We announced the commercial launch of our Zio monitor and Zio long-term continuous monitoring service in Austria, the Netherlands, Spain, and Switzerland. This is an important milestone as the global burden of arrhythmias continues to rise. Learn more here: https://bit.ly/4giljsb
As multiple vital signs and digital data assets are increasingly combined to generate clinical insights, we’re excited to share that today we announced an exclusive license agreement with BioIntelliSense, Inc to use their patented pulse oximetry, accelerometry and trending non-invasive blood pressure technologies for use within the ambulatory cardiac monitoring (ACM) market. Read more here: https://bit.ly/3AS3rnH
As multiple vital signs and digital data assets are increasingly combined to generate clinical insights, we’re excited to share that today we announced an exclusive license agreement with BioIntelliSense, Inc to use their patented pulse oximetry, accelerometry and trending non-invasive blood pressure technologies for use within the ambulatory cardiac monitoring (ACM) market. Read more here: https://bit.ly/3AS3rnH
Joining iRhythm, you'll have the opportunity to grow your skills and your career while impacting the lives of people around the world. Everyone has a chance to make a difference as we work together to push the boundaries of what's possible. In order to build the future, we need curious and innovative problem solvers like you.
Careers | iRhythm
We are dedicated to improving the work lives of our employees, and we couldn't be more thankful for our own Paula Miller, director of Diversity, Equity, Inclusion, and Belonging in helping us achieve exactly that. Learn the importance of DEI work and more about Paula on The Muse: https://bit.ly/44viflZ #iRhythmtech
Why DEI Work Is Mission Critical